Serotonergic and noradrenergic modulation of emotion processing by single dose antidepressants

Neuropsychopharmacology

Volumn 35, Issue 2, 2010, Pages 521-533

  Brühl, Annette Beatrix ^a   Kaffenberger, Tina ^a   Herwig, Uwe ^a,b  

^a UNIVERSITY HOSPITAL OF PSYCHIATRY   (Switzerland)

^b UNIVERSITY OF ULM   (Germany)

Author keywords

Citalopram; Depression; Emotion processing; Functional imaging; Reboxetine; Treatment

Indexed keywords

CITALOPRAM; PLACEBO; REBOXETINE;

ADULT; ANTICIPATION; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DRUG MECHANISM; DYSPHAGIA; EMOTION; FATIGUE; FEMALE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HALLUCINATION; HUMAN; HUMAN EXPERIMENT; MALE; NAUSEA; NORADRENERGIC SYSTEM; OCCIPITAL CORTEX; PARIETAL LOBE; PERCEPTION; PREFRONTAL CORTEX; PRIORITY JOURNAL; PSEUDOHALLUCINATION; REFLEX; SEROTONINERGIC SYSTEM; SIDE EFFECT; SINGLE BLIND PROCEDURE; SINGLE DRUG DOSE; SLEEP; SLEEP DISORDER; TASK PERFORMANCE; THALAMUS; XEROSTOMIA;

ADULT; ANALYSIS OF VARIANCE; ANTIDEPRESSIVE AGENTS; BRAIN; BRAIN MAPPING; CITALOPRAM; EXPRESSED EMOTION; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; MORPHOLINES; NEURAL PATHWAYS; NOREPINEPHRINE; OXYGEN; PHOTIC STIMULATION; SEROTONIN; SINGLE-BLIND METHOD; YOUNG ADULT;

EID: 72449137580     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/npp.2009.159     Document Type: Article

References (77)

1. Abler B, Erk S, Herwig U, Walter H (2007). Anticipation of aversive stimuli activates extended amygdala in unipolar depression. J Psychiatr Res 6: 511-522.
2. Anderson IM, Del-Ben CM, McKie S, Richardson P, Williams SR, Elliott R et al (2007). Citalopram modulation of neuronal responses to aversive face emotions: a functional MRI study. Neuroreport 13: 1351-1355.
3. Annett M (1970). A classification of hand preference by association analysis. Br J Psychol 3: 303-321.
4. Aston-Jones G, Rajkowski J, Cohen J (1999). Role of locus coeruleus in attention and behavioral flexibility. Biol Psychiatry 9: 1309-1320. (Pubitemid 30114448)
5. Beck AT (2005). The current state of cognitive therapy: a 40-year retrospective. Arch Gen Psychiatry 9: 953-959.
6. Beck AT (1967). Depression: Clinical, Experimental, and Theoretical Aspects. Harper & Row: New York.
7. Berridge CW (2008). Noradrenergic modulation of arousal. Brain Res Rev 1: 1-17.
8. Berton O, Nestler EJ (2006). New approaches to antidepressant drug discovery: beyond monoamines. Nat Rev Neurosci 2: 137-151.
9. Bhagwagar Z, Cowen PJ, Goodwin GM, Harmer CJ (2004). Normalization of enhanced fear recognition by acute SSRI treatment in subjects with a previous history of depression. Am J Psychiatry 1: 166-168.
10. Bigos KL, Pollock BG, Aizenstein HJ, Fisher PM, Bies RR, Hariri AR (2008). Acute 5-HT reuptake blockade potentiates human amygdala reactivity. Neuropsychopharmacology 13: 3221-3225.
11. Bruder GE, Sedoruk JP, Stewart JW, McGrath PJ, Quitkin FM, Tenke CE (2008). Electroencephalographic alpha measures predict therapeutic response to a selective serotonin reuptake inhibitor antidepressant: pre-and post-treatment findings. Biol Psychiatry 12: 1171-1177.
12. Burghardt NS, Bush DE, McEwen BS, LeDoux JE (2007). Acute selective serotonin reuptake inhibitors increase conditioned fear expression: blockade with a 5-HT(2C) receptor antagonist. Biol Psychiatry 10: 1111-1118.
13. Burghardt NS, Sullivan GM, McEwen BS, Gorman JM, LeDoux JE (2004). The selective serotonin reuptake inhibitor citalopram increases fear after acute treatment but reduces fear with chronic treatment: a comparison with tianeptine. Biol Psychiatry 12: 1171-1178.
14. Chua P, Krams M, Toni I, Passingham R, Dolan R (1999). A functional anatomy of anticipatory anxiety. Neuroimage 6(Pt 1): 563-571.
15. Clark L, Chamberlain SR, Sahakian BJ (2009). Neurocognitive mechanisms in depression: implications for treatment. Annu Rev Neurosci 32: 57-74.
16. Cools R, Roberts AC, Robbins TW (2008). Serotoninergic regulation of emotional and behavioural control processes. Trends Cogn Sci 1: 31-40.
17. Craig AD (2002). How do you feel? Interoception: the sense of the physiological condition of the body. Nat Rev Neurosci 8: 655-666.
18. Critchley HD, Mathias CJ, Dolan RJ (2001). Neural activity in the human brain relating to uncertainty and arousal during anticipation. Neuron 2: 537-545.
19. De Martino B, Strange BA, Dolan RJ (2008). Noradrenergic neuromodulation of human attention for emotional and neutral stimuli. Psychopharmacology (Berl) 1: 127-136.
20. Del-Ben CM, Deakin JF, McKie S, Delvai NA, Williams SR, Elliott R et al (2005). The effect of citalopram pretreatment on neuronal responses to neuropsychological tasks in normal volunteers: an FMRI study. Neuropsychopharmacology 9: 1724-1734.
21. DeRubeis RJ, Siegle GJ, Hollon SD (2008). Cognitive therapy vs medication for depression: treatment outcomes and neural mechanisms. Nat Rev Neurosci 10: 788-796.
22. Drevets WC (2001). Neuroimaging and neuropathological studies of depression: implications for the cognitive-emotional features of mood disorders. Curr Opin Neurobiol 2: 240-249.
23. Eggert D (1974). Eysenck-Persönlichkeits-Inventar EPI. Verlag für Psychologie, Dr CJ Hogrefe: Göttingen.
24. Eysenck HJ, Eysenck SB (1964). Manual of the Eysenck Personality Inventory. University of London Press: London.
25. Fleishaker JC (2000). Clinical pharmacokinetics of reboxetine, a selective norepinephrine reuptake inhibitor for the treatment of patients with depression. Clin Pharmacokinet 6: 413-427.
26. Flint J, Munafo MR (2007). The endophenotype concept in psychiatric genetics. Psychol Med 2: 163-180.
27. Forster GL, Feng N, Watt MJ, Korzan WJ, Mouw NJ, Summers CH et al (2006). Corticotropin-releasing factor in the dorsal raphe elicits temporally distinct serotonergic responses in the limbic system in relation to fear behavior. Neuroscience 2: 1047-1055.
28. Fuster JM (2000). Executive frontal functions. Exp Brain Res 1: 66-70.
29. Glover GH (1999). Deconvolution of impulse response in event-related BOLD fMRI. Neuroimage 4: 416-429.
30. Gotlib IH, Hamilton JP (2008). Neuroimaging and depression: current status and unresolved issues. Curr Dir Psychol Sci 2: 159-163.
31. Gottesman II, Gould TD (2003). The endophenotype concept in psychiatry: etymology and strategic intentions. Am J Psychiatry 4: 636-645.
32. Harmer CJ, Bhagwagar Z, Perrett DI, Vollm BA, Cowen PJ, Goodwin GM (2003). Acute SSRI administration affects the processing of social cues in healthy volunteers. Neuropsycho-pharmacology 1: 148-152.
33. Harmer CJ, Shelley NC, Cowen PJ, Goodwin GM (2004). Increased positive vs negative affective perception and memory in healthy volunteers following selective serotonin and norepinephrine reuptake inhibition. Am J Psychiatry 7: 1256-1263.
34. Herwig U, Abler B, Walter H, Erk S (2007a). Expecting unpleasant stimuliFan fMRI study. Psychiatry Res 1: 1-12.
35. Herwig U, Baumgartner T, Kaffenberger T, Brühl A, Kottlow M, Schreiter-Gasser U et al (2007b). Modulation of anticipatory emotion and perception processing by cognitive control. Neuroimage 2: 652-662.
36. Herwig U, Brühl AB, Kaffenberger T, Baumgartner T, Boeker H, Jäncke L (2009). Neural correlates of 'pessimistic' attitude in depression. Psychol Med 1: 1-12.
37. Herwig U, Kaffenberger T, Baumgartner T, Jäncke L (2007c). Neural correlates of a 'pessimistic' attitude when anticipating events of unknown emotional valence. Neuroimage 2: 848-858.
38. Hirschfeld RM (2000). History and evolution of the monoamine hypothesis of depression. J Clin Psychiatry 61(Suppl 6): 4-6.
39. Holsboer F (2008). How can we realize the promise of personalized antidepressant medicines? Nat Rev Neurosci 8: 638-646.
40. Houle S, Ginovart N, Hussey D, Meyer JH, Wilson AA (2000). Imaging the serotonin transporter with positron emission tomography: initial human studies with [11C]DAPP and [11C]DASB. Eur J Nucl Med 11: 1719-1722.
41. Hyttel J (1982). CitalopramFpharmacological profile of a specific serotonin uptake inhibitor with antidepressant activity. Prog Neuropsychopharmacol Biol Psychiatry 3: 277-295.
42. Jensen J, McIntosh AR, Crawley AP, Mikulis DJ, Remington G, Kapur S (2003). Direct activation of the ventral striatum in anticipation of aversive stimuli. Neuron 6: 1251-1257.
43. Joubert AF, Sanchez C, Larsen F (2000). Citalopram. Hum Psychopharmacol 6: 439-451.
44. Katz MM, Tekell JL, Bowden CL, Brannan S, Houston JP, Berman N et al (2004). Onset and early behavioral effects of pharmacologically different antidepressants and placebo in depression. Neuropsychopharmacology 3: 566-579.
45. Kent JM (2000). SNaRIs, NaSSAs, and NaRIs: new agents for the treatment of depression. Lancet 9207: 911-918.
46. Kukolja J, Schlapfer TE, Keysers C, Klingmuller D, Maier W, Fink GR et al (2008). Modeling a negative response bias in the human amygdala by noradrenergic-glucocorticoid interactions. J Neurosci 48: 12868-12876.
47. Kumar P, Waiter G, Ahearn T, Milders M, Reid I, Steele JD (2008). Abnormal temporal difference reward-learning signals in major depression. Brain 8: 2084-2093.
48. Kung M-P, Choi S-R, Hou C, Zhuang Z-P, Foulon C, Kung HF (2004). Selective binding of 2-[125I]iodo-nisoxetine to norepi-nephrine transporters in the brain. Nucl Med Biol 5: 533-541.
49. Lang PJ, Bradley MM, Cuthbert BN (2005). International Affective Picture System (IAPS): Affective Ratings of Pictures and Instruction Manual. Technical Report A-6. Center for Research in Psychophysiology, University of Florida: Gainesville, FL.
50. Laruelle M, Vanisberg MA, Maloteaux JM (1988). Regional and subcellular localization in human brain of [3H]paroxetine binding, a marker of serotonin uptake sites. Biol Psychiatry 3: 299-309.
51. Laux L, Glanzmann P, Schaffner P, Spielberger CD (1981). Das State-Trait-Angstinventar (Testmappe mit Handanweisung, Fragebogen STAI-G Form X1 und Fragebogen STAI-G Form X2). Beltz: Weinheim.
52. Logan J, Wang G-j, Telang F, Fowler JS, Alexoff D, Zabroski J et al (2007). Imaging the norepinephrine transporter in humans with (S,S)-[11C]O-methyl reboxetine and PET: problems and progress. Nucl Med Biol 6: 667-679.
53. Mayberg HS (2003). Modulating dysfunctional limbic-cortical circuits in depression: towards development of brain-based algorithms for diagnosis and optimised treatment. Br Med Bull 65: 193-207.
54. McKie S, Del-Ben C, Elliott R, Williams S, del Vai N, Anderson I et al (2005). Neuronal effects of acute citalopram detected by pharmacoMRI. Psychopharmacology (Berl) 4: 680-686.
55. Miskowiak K, Papadatou-Pastou M, Cowen PJ, Goodwin GM, Norbury R, Harmer CJ (2007). Single dose antidepressant administration modulates the neural processing of self-referent personality trait words. Neuroimage 3: 904-911.
56. Murphy SE, Norbury R, O'Sullivan U, Cowen PJ, Harmer CJ (2009). Effect of a single dose of citalopram on amygdala response to emotional faces. Br J Psychiatry 6: 535-540.
57. Nemeroff CB, Owens MJ (2002). Treatment of mood disorders. Nat Neurosci 5(Suppl): 1068-1070.
58. Nitschke JB, Sarinopoulos I, Mackiewicz KL, Schaefer HS, Davidson RJ (2006). Functional neuroanatomy of aversion and its anticipation. Neuroimage 1: 106-116.
59. Norbury R, Mackay CE, Cowen PJ, Goodwin GM, Harmer CJ (2008). The effects of reboxetine on emotional processing in healthy volunteers: an fMRI study. Mol Psychiatry 11: 1011-1020.
60. O'Carroll RE, Papps BP (2003). Decision making in humans: the effect of manipulating the central noradrenergic system. J Neurol Neurosurg Psychiatry 3: 376-378.
61. Onur OA, Walter H, Schlaepfer TE, Rehme AK, Schmidt C, Keysers C et al (2009). Noradrenergic enhancement of amygdala responses to fear. Soc Cogn Affect Neurosci 2: 119-126.
62. Phillips ML, Drevets WC, Rauch SL, Lane R (2003). Neurobiology of emotion perception II: implications for major psychiatric disorders. Biol Psychiatry 5: 515-528.
63. Ploghaus A, Tracey I, Gati JS, Clare S, Menon RS, Matthews PM et al (1999). Dissociating pain from its anticipation in the human brain. Science 5422: 1979-1981.
64. Rose EJ, Simonotto E, Spencer EP, Ebmeier KP (2006). The effects of escitalopram on working memory and brain activity in healthy adults during performance of the n-back task. Psycho-pharmacology (Berl) 3: 339-347.
65. Schildkraut JJ (1965). The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry 5: 509-522.
66. Schloss P, Henn FA (2004). New insights into the mechanisms of antidepressant therapy. Pharmacol Ther 1: 47-60.
67. Schou M, Halldin C, Pike VW, Mozley PD, Dobson D, Innis RB et al (2005). Post-mortem human brain autoradiography of the norepinephrine transporter using (S,S)-[18F]FMeNER-D2. Eur Neuropsychopharmacol 5: 517-520.
68. Smith HR, Beveridge TJ, Porrino LJ (2006). Distribution of norepinephrine transporters in the non-human primate brain. Neuroscience 2: 703-714.
69. Spielberger CD, Gorsuch RL, Lushene RE (1970). State-Trait Anxiety Inventory, Manual for the State-Trait-Anxiety Inventory. Consulting Psychologist Press: Palo Alto, CA.
70. Talairach J, Tournoux P (1988). Co-planar Stereotaxic Atlas of the Human Brain: Three-Dimensional Proportional System. Thieme Medical: New York.
71. Tatsumi M, Groshan K, Blakely RD, Richelson E (1997). Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol 2-3: 249-258.
72. Van der Werf YD, Witter MP, Groenewegen HJ (2002). The intralaminar and midline nuclei of the thalamus. Anatomical and functional evidence for participation in processes of arousal and awareness. Brain Res Brain Res Rev 2-3: 107-140.
73. Varnas K, Halldin C, Hall H (2004). Autoradiographic distribution of serotonin transporters and receptor subtypes in human brain. Hum Brain Mapp 3: 246-260.
74. Vogt BA (2005). Pain and emotion interactions in subregions of the cingulate gyrus. Nat Rev Neurosci 7: 533-544.
75. Wilson AA, Patrick Johnson D, Mozley D, Hussey D, Ginovart N, Nobrega J et al (2003). Synthesis and in vivo evaluation of novel radiotracers for the in vivo imaging of the norepinephrine transporter. Nucl Med Biol 2: 85-92.
76. Wingen M, Kuypers KP, van de Ven V, Formisano E, Ramaekers JG (2008). Sustained attention and serotonin: a pharmaco-fMRI study. Hum Psychopharmacol 3: 221-230.
77. Zung WW (1965). A self-rating depression scale. Arch Gen Psychiatry 12: 63-70.